Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
176 hedge funds and large institutions have $1.39B invested in Five Prime Therapeutics, Inc. in 2016 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 65 increasing their positions, 65 reducing their positions, and 20 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
37% more capital invested
Capital invested by funds: $1.01B → $1.39B (+$373M)
35% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 20
4% more funds holding
Funds holding: 170 → 176 (+6)
0% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 65
94% less call options, than puts
Call options by funds: $380K | Put options by funds: $6.85M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$68.5M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$28.1M |
| 3 |
Goldman Sachs
New York
|
+$22.6M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$19.8M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$13.7M |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$15.4M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$11.6M |
| 3 |
GAM
Gotham Asset Management
New York
|
-$10.9M |
| 4 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$9.72M |
| 5 |
DM
Deerfield Management
New York
|
-$6.54M |
FPRX Hedge Fund Activity: Q3 2016 in Review
176 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q3 2016, worth a combined $1.39B — up 37% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new FPRX positions and 20 closed out — a net gain of 7 holders — while 65 added to existing stakes and 65 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $68.5M. The largest seller was Wellington Management Group, cutting an estimated $15.4M.
- 176 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q3 2016, up from 170 in Q2 2016.
- Funds reported $1.39B of Five Prime Therapeutics, Inc. stock for Q3 2016, up 37% quarter-over-quarter.
- 27 funds opened new Five Prime Therapeutics, Inc. positions in Q3 2016 and 20 closed out, a net change of +7 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q3 2016 was Fidelity Investments, an estimated $68.5M added.
- The largest Five Prime Therapeutics, Inc. seller in Q3 2016 was Wellington Management Group, an estimated $15.4M sold.
Based on aggregated 13F filings for Q3 2016.